96 related articles for article (PubMed ID: 27875318)
21. Correlation of
Parkhomenko AA; Zastrozhin MS; Skryabin V; Ivanchenko VA; Pozdniakov SA; Noskov VV; Zaytsev IA; Denisenko NP; Akmalova KA; Bryun EA; Sychev DA
Psychopharmacol Bull; 2022 Jun; 52(3):58-67. PubMed ID: 35815171
[TBL] [Abstract][Full Text] [Related]
22. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
23. [Glutamate receptors genes polymorphism and the risk of paranoid schizophrenia in Russians and tatars from the Republic of Bashkortostan].
Gareeva AE; Khusnutdinova EK
Mol Biol (Mosk); 2014; 48(5):771-81. PubMed ID: 25842862
[TBL] [Abstract][Full Text] [Related]
24. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.
Lohmann PL; Bagli M; Krauss H; Müller DJ; Schulze TG; Fangerau H; Ludwig M; Barkow K; Held T; Heun R; Maier W; Rietschel M; Rao ML
Pharmacopsychiatry; 2003; 36(2):73-8. PubMed ID: 12734765
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.
Šimić I; Potočnjak I; Kraljičković I; Stanić Benić M; Čegec I; Juričić Nahal D; Ganoci L; Božina N
Pharmacogenomics; 2016 Aug; 17(13):1385-9. PubMed ID: 27469576
[TBL] [Abstract][Full Text] [Related]
26. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
27. The association between cytochrome P450-2D6 genotype and prescription of antiparkinsonian drugs in hospitalized psychiatric patients using antipsychotics: a retrospective follow-up study.
Mulder H; Wilmink FW; Belitser SV; Egberts AC
J Clin Psychopharmacol; 2006 Apr; 26(2):212-5. PubMed ID: 16633157
[No Abstract] [Full Text] [Related]
28. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers.
Gassó P; Papagianni K; Mas S; de Bobadilla RF; Arnaiz JA; Bernardo M; Lafuente A
Pharmacogenomics; 2013 Oct; 14(13):1551-63. PubMed ID: 24088126
[TBL] [Abstract][Full Text] [Related]
29. CYP 2D6 polymorphism and antipsychotic therapy.
Plesnicar BK; Dolzan V; Zalar B
Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
[TBL] [Abstract][Full Text] [Related]
30. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
31. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.
Ivanova SA; Filipenko ML; Vyalova NM; Voronina EN; Pozhidaev IV; Osmanova DZ; Ivanov MV; Fedorenko OY; Semke AV; Bokhan NA
Bull Exp Biol Med; 2016 Mar; 160(5):687-90. PubMed ID: 27021090
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA).
Fedorinov DS; Mirzaev KB; Mustafina VR; Sychev DA; Maximova NR; Chertovskikh JV; Popova NV; Tarabukina SM; Rudykh ZA
Drug Metab Pers Ther; 2018 Dec; 33(4):195-200. PubMed ID: 30325731
[TBL] [Abstract][Full Text] [Related]
33. [Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible?].
Chebotareva AD; Levin OS; Markov DD; Sychev DA; Grishina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(6. Vyp. 2):90-94. PubMed ID: 30346440
[TBL] [Abstract][Full Text] [Related]
34. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
35. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
36. [Brain neurotransmitter systems gene Polymorphism: the Search for pharmacogenetic markers of efficacy of haloperidol in Russians and Tatars].
Gareeva AE; Kinyasheva KO; Galaktionova DY; Sabirov ET; Valinourov RG; Chudinov AV; Zasedatelev AS; Nasedkina TV; Khusnutdinova EK
Mol Biol (Mosk); 2015; 49(6):959-67. PubMed ID: 26710776
[TBL] [Abstract][Full Text] [Related]
37. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
38. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of the cytochrome P450 (CYP1A1) gene polymorphism in the ethnic groups of the Republic of Bashkortostan].
Kochetova OV; Korytina GF; Akhmadishina LZ; Iskhakov GM; Victorova TV
Genetika; 2008 Dec; 44(12):1677-83. PubMed ID: 19178087
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic parameters of bromperidol in Korean subjects.
Lee SY; Kim YG; Kim HG; Kim JW
Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
